

Draft Press Release to announce AtomVie’s collaboration with RLS & UPPI

**AtomVie Global Radiopharma Collaborates with RLS & UPPI to Strengthen its Existing U.S. Radiotherapeutic Distribution Network**

[Locations, Date] - AtomVie Global Radiopharma Inc. (AtomVie), a leading radiopharmaceutical Contract Development and Manufacturing Organization (CDMO), is proud to announce strategic collaborations with Radioisotope Life Sciences Inc. (RLS) and UPPI LLC. (UPPI), two industry leaders in radiopharmacy and logistics. This strategic move is poised to enhance AtomVie’s logistics capabilities within the United States, ensuring the widespread distribution of high-quality radiopharmaceuticals by implementing RLS and UPPI as key partners within AtomVie’s existing U.S. distribution network. AtomVie specializes in the GMP manufacturing and global distribution of radiopharmaceticals, RLS owns and operates radiopharmacies across 18 states, and UPPI, organized as a Group Purchasing Organization (GPO), brings extensive capabilities in logistics and distribution.

Radiopharmaceuticals play a pivotal role in precision medicine solutions, providing innovative and promising treatments for various cancer indications. Recognizing the logistics challenges associated with radiopharmaceuticals, given their short half-lives and the critical importance of timely administration. AtomVie, together with RLS and UPPI will bolster its distribution capabilities and allow life-saving treatments to reach more patients.

“Our commitment to transforming patient lives through high-quality radiopharmaceuticals is at the core of this partnership with RLS and UPPI," commented Bruno Paquin, CEO of AtomVie. He added “These collaborations strengthen our ability to deliver critical radiopharmaceuticals to more locations, ensuring timely access for patients who rely on the products. These partnerships not only meet the current demand but position us for future growth, as we meaningfully expand our manufacturing capacity and add commercial-scale capabilities.”

Under the agreements, AtomVie will leverage RLS’s and UPPI’s extensive radiopharmacy network, as the companies aim to swiftly deliver radiopharmaceuticals to healthcare providers.

RLS CEO Stephen Belcher expressed confidence in the partnership's impact on patient care, stating, *"Sample quote - This collaboration improves access to life-saving radioisotope-based medicines. Together, we are committed to creating an unbroken chain of patient care, from clinical trial to commercial supply"*

John Witkowski, President UPPI highlighted the partnership's positive impact, promoting greater accessibility and enhanced well-being for individuals, stating *"Sample quote - This partnership is a significant step forward in improving access to life-saving radioisotope-based therapeutics and diagnostics. It reflects our joint commitment to delivering precision medicine solutions for patients across the nation."*

As leaders in their respective fields, AtomVie, RLS, and UPPI bring unique expertise to this strategic partnership, offering seamless radiopharmaceutical solutionsand emphasizing their collective goal to revolutionize patient care by providing consistent access to high-quality radiopharmaceutical options nationwide.

About AtomVie Global Radiopharma Inc.

AtomVie is a global leading CDMO for the GMP manufacturing and worldwide distribution of clinical and commercial radiopharmaceuticals. AtomVie offers the full range of scientific, technical, regulatory, quality, logistics and business expertise combined with a specialized infrastructure for the development of radiopharmaceuticals from clinical studies to the commercial marketplace. AtomVie currently serves international clients conducting studies in over 20 countries worldwide. AtomVie is currently building a state-of-art purpose-built, scalable facility of >70,000 sq ft in Hamilton Ontario that is set to be ready in late 2024. For more information, visit <https://www.atomvie.com/>

About RLS Inc.

RLS, please add.

About UPPI LLC

UPPI, please add.